Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR DEL19”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Early research (Phase 1)Looking for participantsNCT06955988
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 120
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Not applicableStudy completedNCT04370860
What this trial is testing

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Who this might be right for
EGFR Exon 19 MutationTumor Progression
National Taiwan University Hospital 1,000
Not applicableLooking for participantsNCT06053099
What this trial is testing

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Who this might be right for
Non Small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique 300
Testing effectiveness (Phase 2)Looking for participantsNCT07206498
What this trial is testing

Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Wayshine Biopharm, Inc. 48
Testing effectiveness (Phase 2)Ended earlyNCT02349633
What this trial is testing

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 65